Download PDF
Thromb Haemost 1992; 68(02): 170-179
DOI: 10.1055/s-0038-1656344
Original Article
Schattauer GmbH Stuttgart

Thrombolytic and Pharmacokinetic Properties of a Recombinant Chimeric Plasminogen Activator Consisting of a Fibrin Fragment D-Dimer Specific Humanized Monoclonal Antibody and a Truncated Single-Chain Urokinase

M Dewerchin
The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
A-M Vandamme
The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
P Holvoet
The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
F De Cock
The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
G Lemmens
The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
H R Lijnen
The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
J-M Stassen
The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
,
D Collen
The Center for Thrombosis and Vascular Research, University of Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 13 November 1991

Accepted after revision 27 February 1992

Publication Date:
03 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

A recombinant chimeric plasminogen activator consisting of a humanized monoclonal antibody specific for cross-linked human fibrin (MA-15C5Hu) and a 32 kDa single-chain urokinase-type plasminogen activator (scu-PA-32k) comprising amino acids Leu144-Leu411, MA-15C5Hu/scu-PA-32k, was previously found to have a 12-fold higher fibrinolytic potency than recombinant scu-PA-32k towards a human plasma clot in a human plasma milieu in vitro (Vandamme et al., Eur J Biochem 1992; 205: 139–46). Therefore, the thrombolytic and pharmacokinetic properties of MA-15C5Hu/scu-PA-32k were compared with those of recombinant single-chain urokinase-type plasminogen activator (scu-PA) in 3 different venous thrombosis models in vivo. In hamsters with a pulmonary embolus consisting of a human plasma clot, the thrombolytic potency (% lysis per dose in mg/kg administered) of MA-15C5Hu/scu-PA-32k was 23-fold higher than that of scu-PA (p <0.0005). In rabbits with a jugular vein clot prepared from human plasma, the thrombolytic potency of MA-15C5Hu/scu-PA-32k was 11-fold higher than that of scu-PA (p = 0.012). In baboons with an autologous whole blood clot in the femoral vein, the chimera had a 5-fold higher thrombolytic potency than scu-PA. In all three animal species, the clearance of the chimera was 10- to 27-fold reduced as compared to scu-PA. The specific thrombolytic activity (% lysis per µg/ml steady-state plasma u-PA antigen) was increased up to 7-fold with MA-15C5Hu/scu-PA-32k as compared with scu-PA, which is indicative of targeting of the chimera to the clot. No fibrinogen breakdown or α2-antiplasmin depletion was observed during thrombolysis with the chimera.

Thus, MA-15C5Hu/scu-PA-32k constitutes a recombinant chimeric plasminogen activator with a significantly enhanced thrombolytic potency in 3 different animal models of venous thrombosis.

 

  • References

  • 1 Haber E, Quertermous T, Matsueda GR, Runge MS. Innovative approaches to plasminogen activator therapy. Science 1989; 243: 51-56
    CrossrefPubMedGoogle Scholar
  • 2 Dewerchin M, Collen D. Enhancement of the thrombolytic potency of plasminogen activators by conjugation with clot-specific monoclonal antibodies. Bioconj Chem 1991; 2: 293-300
    CrossrefPubMedGoogle Scholar
  • 3 Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci USA 1987; 84: 7659-7662
    CrossrefPubMedGoogle Scholar
  • 4 Bode C, Runge MS, Schönermark S, Eberle T, Newell JB, Kübler W, Haber E. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Circulation 1990; 81: 1974-1980
    CrossrefPubMedGoogle Scholar
  • 5 Dewerchin M, Lijnen HR, Van Hoef B, De Cock F, Collen D. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin. Eur J Biochem 1989; 185: 141-149
    CrossrefPubMedGoogle Scholar
  • 6 Declerck PJ, Mombaerts P, Holvoet P, De Mol M, Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemostas 1987; 58: 1024-1029
    PubMedGoogle Scholar
  • 7 Holvoet P, Stassen JM, Hashimoto Y, Spriggs D, Devos P, Collen D. Binding properties of monoclonal antibodies against human fragment D-dimer of cross-linked fibrin to human plasma clots in an in vivo model in rabbits. Thromb Haemostas 1989; 61: 307-313
    PubMedGoogle Scholar
  • 8 Collen D, Dewerchin M, Stassen JM, Kieckens L, Lijnen HR. Thrombolytic and pharmacokinetic properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin. Fibrinolysis 1989; 3: 197-202
    PubMedGoogle Scholar
  • 9 Collen D, Dewerchin M, Rapold H, Lijnen HR, Stassen JM. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin, in a baboon venous thrombosis model. Circulation 1990; 82: 1744-1753
    CrossrefPubMedGoogle Scholar
  • 10 Vandamme A-M, Dewerchin M, Lijnen HR, Bernar H, Bulens F, Nelles L, Collen D. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase. Eur J Biochem 1992; 205: 139-146
    CrossrefPubMedGoogle Scholar
  • 11 Vandamme AM, Bulens F, Bernar H, Nelles L, Lijnen HR, Collen D. Construction and characterization of a recombinant murine monoclonal antibody directed against human fibrin fragment D-dimer. Eur J Biochem 1990; 192: 767-775
    CrossrefPubMedGoogle Scholar
  • 12 Bulens F, Vandamme AM, Bernar H, Nelles L, Lijnen HR, Collen D. Construction and characterization of a functional chimeric murine-human antibody directed against human fibrin fragment D-dimer. Eur J Biochem 1991; 195: 235-242
    CrossrefPubMedGoogle Scholar
  • 13 Lijnen HR, Nelles L, Holmes WE, Collen D. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu 411) of recombinant single-chain urokinase-type plasminogen activator. J Biol Chem 1988; 263: 5594-5598
    PubMedGoogle Scholar
  • 14 Astrup T, Muellertz S. Fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 1952; 40: 346-351
    CrossrefPubMedGoogle Scholar
  • 15 Declerck PJ, Van Keer L, Verstreken M, Collen D. An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA. Thromb Haemostas 1992; 67: 95-100
    PubMedGoogle Scholar
  • 16 Vermylen C, De Vreker RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen: the fibrin polymerization test (F. P. T.). Clin Chim Acta 1963; 8: 418-424
    PubMedGoogle Scholar
  • 17 Zamarron C, Lijnen HR, Van Hoef B, Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology. Thromb Haemostas 1984; 52: 19-23
    PubMedGoogle Scholar
  • 18 Stassen JM, Vanlinthout I, Lijnen HR, Collen D. A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents. Fibrinolysis 1990; 4: 15-21
    PubMedGoogle Scholar
  • 19 Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest 1983; 71: 368-376
    PubMedGoogle Scholar
  • 20 Gibaldi M, Perrier D. Pharmacokinetics. Marcel Dekker, Inc.; New York: 1983: 45-111
    Google Scholar
  • 21 Berman S, Schoenfeld R. Invariants in experimental data on linear kinetics and the formulation of models. J Appl Physiol 1956; 27: 1361-1370
    CrossrefPubMedGoogle Scholar
  • 22 Lijnen HR, Nelles L, Van Houtte E, Collen D. Pharmacokinetic properties of mutants of recombinant single chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, IIe159 and IIe160 . Fibrinolysis 1990; 4: 211-214
    PubMedGoogle Scholar
  • 23 Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemostas 1987; 58: 1078-1084
    PubMedGoogle Scholar
  • 24 Runge MS, Quertermous T, Zavodny PJ, Love TW, Bode C, Freitag M, Shaw SY, Huang PL, Chou CC, Mullins D, Schnee JM, Savard CE, Rothenberg ME, Newell JB, Matsueda GR, Haber E. A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. Proc Natl Acad Sci USA 1991; 88: 10337-10341
    CrossrefPubMedGoogle Scholar
  • 25 Haber E. Can plasminogen activators be improved?. Circulation 1990; 82: 1874-1876
    CrossrefPubMedGoogle Scholar
  • 26 Rodwell JD. Engineering monoclonal antibodies. Nature 1989; 342: 99-100
    CrossrefPubMedGoogle Scholar
  • 27 Dewerchin M, Lijnen HR, Stassen JM, De Cock F, Quertermous T, Ginsberg MH, Plow EF, Collen D. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo. Blood 1991; 78: 1005-1018
    PubMedGoogle Scholar
  • 28 Holvoet P, Laroche Y, Lijnen HR, Van Cauwenberghe R, Demarsin E, Brouwers E, Matthyssens G, Collen D. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer specific antibody and a truncated single-chain urokinase. J Biol Chem 1991; 266: 19717-19724
    PubMedGoogle Scholar